Intra-Cellular Therapies

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intra-Cellular Therapies (ITCI) reports stellar Q4 performance and eyes market expansion

Intra-Cellular Therapies (ITCI) delivered strong financial performance in Q4 2022, driven by robust sales growth of CAPLYTA and a focus on expanding clinical programs.
While facing challenges in managing expenses and navigating market dynamics, the company is well-positioned to capitalize on opportunities in new indications and patient education initiatives.
ITCI's strategic investments in innovation and market expansion underscore its commitment to long-term growth and addressing mental health needs through novel treatment options.

Intra-Cellular Therapies reports robust Q1 performance and growth prospects

ITCI's strong Q1 performance driven by CAPLYTA and promising results from lumateperone studies position the company well for future growth.
Addressing unmet needs in MDD and bipolar depression, along with ongoing pipeline progress, showcases ITCI's commitment to innovation in neuropsychiatric treatments.
While facing challenges in market share data and increasing expenses, opportunities lie in expanding sales force, new indications for pipeline programs, and driving awareness for CAPLYTA.

Intra-Cellular Therapies (ITCI) reports strong Q2 performance and expands treatment portfolio

Intra-Cellular Therapies (ITCI) demonstrated robust performance in Q2, driven by strong revenue growth and promising developments in its product portfolio.
The company's financial strength, innovative pipeline, and focus on addressing unmet medical needs position it well for future growth and success.
While facing challenges in revenue guidance clarity and resource allocation, ITCI has opportunities to expand its market reach and improve patient outcomes.
By leveraging its strengths and addressing challenges effectively, Intra-Cellular Therapies (ITCI) can capitalize on opportunities to drive continued growth and innovation.

Intra-Cellular Therapies (ITCI) excels in Q3, eyes market expansion

Intra-Cellular Therapies (ITCI) showcased strong financial performance and growth prospects in Q3 2023, driven by CAPLYTA's success and pipeline advancements.
While the company faces challenges in sustaining growth and navigating regulatory complexities, opportunities in market expansion and innovation are key for future success.
ITCI's focus on expanding indications, clinical advancements, and financial strength position it well for continued growth and leadership in the pharmaceutical industry.

Intra-Cellular Therapies (ITCI) reports robust growth and strategic expansion

Intra-Cellular Therapies (ITCI) delivered a strong performance in 2023, with robust revenue growth and strategic plans for pipeline advancement and market expansion.
The company faces challenges in managing expenses, optimizing market penetration, and navigating competitive dynamics, but opportunities in sales growth and innovation are evident.
Overall, Intra-Cellular Therapies (ITCI) is well-positioned for continued success, with a focus on driving growth through product differentiation and market positioning.

Intra-Cellular Therapies (ITCI) reports strong Q1 earnings and eyes market expansion

Intra-Cellular Therapies (ITCI) delivered strong Q1 2024 earnings driven by robust CAPLYTA sales and positive results in MDD studies, positioning the company for future growth.
With a solid financial position, a broad label strategy, and a focus on pipeline expansion, ITCI is well-equipped to capitalize on market opportunities and drive long-term success.
While facing near-term uncertainties and challenges, ITCI's strategic initiatives and ongoing studies present significant opportunities for expanding its market reach and revenue potential.
Overall, ITCI's commitment to developing innovative medicines and its market acceptance indicate a promising outlook for sustained growth and value creation.

Intra-Cellular Therapies (ITCI) reports robust Q3 performance and eyes market expansion

Intra-Cellular Therapies (ITCI) delivered strong financial performance in Q3 2024, driven by CAPLYTA's sales growth and strategic investments in R&D.
The company's focus on innovation, with new program initiations and pipeline advancements, positions it well for future growth and market expansion.
While facing challenges in a competitive market and cost management, ITCI's solid financial position and promising pipeline offer opportunities for sustained success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in Bedminster, NJ.

PulteGroup

Clear Channel Outdoor Holdings

Bad news in several forms hit some stocks despite a strong session for the overall market.

Why PulteGroup, Intra-Cellular Therapies, and Clear Channel Outdoor Slumped Today

Intra-Cellular reported complex data that enshrouded the market with confusion and thereby caused the stock to tumble. Patients on the placebo and lumateperone experienced a strong response in Study 401.

Intra-Cellular Therapies: Poised To Rally

I started a long position in the stock last week on the dip and added more today.

Buying Intra-Cellular Therapies On The Dip: Investment Thesis

Buying Intracellular Therapies On The Dip: Investment Thesis

Intra-Cellular Therapies posted mixed results from its two late-stage studies using lumateperone to treat patients with bipolar depression.

Intra-Cellular Therapies Falls On Mixed Data, But Main Event With FDA Is Rapidly Approaching

Potential for new indication of lumateperone.

Intra-Cellular - Potential Game Changer

Intra-Cellular Therapies' (ITCI) lead candidate fails to meet primary endpoint in one of the phase III studies evaluating it in bipolar depression patients. Shares fall.

Intra-Cellular Therapies' Candidate Fails in Phase III Study

Coherus BioSciences

Deutsche Bank

Why Deutsche Bank, Intra-Cellular Therapies, and Coherus BioSciences Slumped Today

Investors disliked the biotech's bad news a lot more than they liked its good news.

Why Intra-Cellular Therapies Is Tanking Today

Developer of treatments for neuropsychiatric and neurologic disorders, Intra-Cellular Therapies (NYSE: ITCI) today had a large opening gap of -22.59%.

What Caused The Opening Gap In Intra-Cellular Therapies?

Intra-Cellular Therapies Inc. (NASDAQ: ITCI) shares dipped on Monday after the company announced top-line results from its two late-stage trial in patients with bipolar depression.

Why Intra-Cellular Therapies’ Depression Study Is Nothing to Smile About

Shares of biotech Intra-Cellular Therapies ITCI, -1.10% fell 15% in premarket trade Monday after the company announced disappointing results from a late-stage trial of its lead drug candidate lumateperone, a potential bipolar depression treatment.

Intra-Cellular Therapies stock down 15% after disappointing Phase 3 trial results

Intra-Cellular Therapies (NASDAQ: ITCI) shares resumed trading after the company released mixed study results from two Phase 3 clinical trials evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with bipolar depression.

Intra-Celluar Therapies Falls Following Results For Treatment Of Bipolar Depression

Intra-Cellular Therapies Inc. icti on Monday reported positive results from two late-stage trials of a treatment for bipolar depression.

Intra-Cellular announces positive results in late-stage trials of treatment for bipolar depression

AngioDynamics

Biotech stocks saw muted sentiment in the holiday-shortened week ending July 5 after a strong rebound in the later part of the previous week.

The Week Ahead In Biotech: Conferences, Clinical Trial Readouts And Earnings

Acer Therapeutics

Biohaven Pharmaceutical Hld

Celgene

Karyopharm Therapeutics

Merck

The FDA went overdrive in the month of June, deciding on several regulatory applications before the July 4 holiday.

Attention Biotech Investors: Mark Your Calendar For These July 2019 PDUFA Dates

Chemical Financial

Golden Entertainment

Guess?

Occidental Petroleum

Park-Ohio Holdings

Sharps Compliance

There are many reasons why an insider may sell their company's stock. But they only buy it for one reason -- to profit.

7 Stocks on Sale the Insiders Are Buying.

Despite one failed Phase 3 trial, Intra-Cellular Therapeutics lead candidate for schizophrenia (ITI-007) appears headed for approval in September 2019, owing to its superior safety and tolerability profile versus standard-of-care.

Intra-Cellular Therapies: Key Catalyst On The Horizon

Intra-Cellular Therapies Inc. (ITCI) CEO Sharon Mates on Q1 2019 Results - Earnings Call Transcript

Intra-Cellular could be the first company to fully transform anti-depressant market.

News for Intra-Cellular Therapies Stock (ITCI)